Best Cardiac and Vascular Disorders Companies in Central District, Israel
The 30 best Cardiac and Vascular Disorders companies in Central District, Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: CathWorks.
Ranked: Best Cardiac and Vascular Disorders companies in Central District
| # | Company | Disclosed funding | Last round | Stage | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CathWorks Developer of angiogram-based physiology measurement solution | $151M | 52 mo ago | Acquired | 74 | 2013 | Ifat Lavi Founder & CTO | 178 patents AI-driven analysis and visualization of coronary angiography and vascular lesion assessment | — |
| 2 | Pi-Cardia Developer of non-implant device for valve repair | $40M | 79 mo ago | Series D | 50 | 2009 | Erez Golan Co-Founder & CEO | 62 patents Transcatheter heart valve cutting, laceration, and calcification removal devices | — |
| 3 | OrSense Provider of non-invasive sensing technology for body vitals measurement | $33M | 186 mo ago | Series B | 24 | 1996 | Yoav Reisman CEO | 60 patents Non‑invasive optical blood analysis for point‑of‑care diagnostic monitoring | — |
| 4 | Laminate Medical Device to prevent AV Fistula failure by promoting their maturation and patency | $20M | 84 mo ago | Series C | 20 | 2012 | Eyal Orion Co-Founder & Board Member | — | — |
| 5 | Endoron Medical Manufacturer of endovascular suture-like device for cardiovascular treatment 37Moat top 25%Patents top 31%Innovation top 33%Funding top 39% All 7 signals ▾Moattop 25% Patentstop 31% Innovationtop 33% Fundingtop 39% Talentbottom 49% Globalbottom 43% Marketbottom 28% Moat: Editorial + unicorn rating 7/10 · IP moat: 38 patents Patents: 38 patents matched (strict assignee match) · 30 filings since 2022 vs 8 in 2017-21 rank vs industry peers · Fliar Intelligence Index 37/100 | $15M | 28 mo ago | Series A | 10 | 2019 | Ron Karmeli Co-Founder & CMO | 38 patents Intravascular graft anchoring and catheter-based vascular closure devices | — |
| 6 | Angioslide Embolic capture device integrated with angioplasty balloon to prevent distal embolization | $15M | 166 mo ago | Series B | 12 | 2005 | — | 80 patents Drug‑coated balloon catheters for targeted vascular drug delivery and angioplasty | — |
| 7 | Kyma Remote patient monitoring solutions for chronic cardiac patients | $10M | 157 mo ago | Acqui-Hired | 11 | 2008 | Uriel Weinstein Co-founder | — | — |
| 8 | Ovalum Vascular Solutions for chronic and acute total occlusions in the coronary and peripheral arteries. | $4M | 242 mo ago | Deadpooled | — | 2005 | Noam Shamay Founder & CEO | — | — |
| 9 | Bendit Technologies Steerable & torque able microcatheter for better navigation | $4M | 109 mo ago | Series A | 23 | 2013 | — | 6 patents Robotic catheter steering mechanisms for minimally invasive medical procedures. | — |
| 10 | Oxitone Wrist-based Pulse Oximetry health monitor | $3M | 138 mo ago | Seed | 11 | 2010 | Leon Eisen Founder & Executive Chairman | — | — |
| 11 | Leviticus Cardio Wireless power transfer system to cater the power needs of VAD Implants | $3M | 94 mo ago | Seed | 7 | 2008 | — | 30 patents Implantable cardiac device power management, hybrid energy, batteries, and patient monitoring systems. | — |
| 12 | Nicast Nano fabric biomaterials for vascular access & wound care | $3M | 136 mo ago | Deadpooled | 11 | 1995 | Alex Dubson Founder & CTO | 86 patents Patents concentrated in health & consumer products | — |
| 13 | Eximo Medical Hybrid catheters for vascular procedures | $2M | 135 mo ago | Acquired | 15 | 2012 | — | 74 patents Intravascular laser ablation and lesion characterization catheters for vascular interventions | — |
| 14 | Biobeat Body vitals monitoring solution 48Tech top 34%Growth top 35%Product top 40%Funding top 46% All 7 signals ▾Techtop 34% Growthtop 35% Producttop 40% Fundingtop 46% Moattop 48% Globalbottom 38% Marketbottom 37% Tech: 38 technologies across 5/8 capability areas · Cloud: Amazon Web Services, Cloudflare Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $1M | 10 mo ago | Series B | 29 | 2014 | — | — | — |
| 15 | VVT Medical Percutaneous delivery of vascular embolic device for the treatment of varicose veins 37Product top 14%Growth top 35%Funding top 44%Patents top 45% All 9 signals ▾Producttop 14% Growthtop 35% Fundingtop 44% Patentstop 45% Moattop 45% Innovationtop 47% Techtop 48% Globalbottom 37% Marketbottom 24% Product: 4 distinct product lines · Company stage: Post IPO Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 37/100 | $779K | 7 mo ago | Late Stage | 11 | 2007 | — | 78 patents Patents concentrated in health & consumer products | — |
| 16 | Elfi-Tech Developing technology for non-invasive physiological monitoring and diagnostics | $113K | 91 mo ago | Funding Raised | 14 | 2006 | Ilya Fine Founder & CEO | 42 patents Non‑invasive optical blood‑pressure and hemodynamic monitoring using dynamic light scattering | — |
Top 12 Cardiac and Vascular Disorders companies in Central District
#1
Late Stage · Kfar Saba, Central District · founded 2007 · 11 employees$779.2Kraised▾
VVT Medical has developed a medical technology for the treatment of varicose veins. Its procedure called V-Block includes a percutaneous delivery of vascular embolic device (called v-block device) into the proximal great saphenous vein (GSV) and induce a concomitant liquid sclerotherapy using its proprietary dual procedure syringe system by the simultaneous aspiration of the blood and the discharging of the sclerosing agent. Claims that the procedure requires no anesthesia and requires minimal post procedure care.
- Apr 2026Post IPO$779.2K
#2
Series B · Petah Tikva, Central District · founded 2014 · 29 employees$1Mraised▾
Biobeat offers a non-invasive body vitals monitoring wearable solution. It uses reflective Pulse Oximetry technology with their algorithm to allow for constant measurements of related body vitals. Sensor delivers a range of body vitals measurement including consciousness, saturation, pulse, temperature and perspiration. The devices are connected to a mobile app or a central monitoring system where the user's data is stored. Data is then compared against a person's normal levels to identify life-threatening situations. It also allows data sharing with doctors and caregivers. They have released their products for athletes and Hospitals. Founded by Arik Ben Ishai Director of startups in the Rocket and Space Department of the Ministry of Defense, Israel.
- Dec 2025Series B$50M
- Oct 2019Grant (prize money)$188.5K
- Jun 2016Angel$1M
#3
Series A · Kfar Saba, Central District · founded 2019 · 10 employees$15Mraised▾
Manufacturer of endovascular suture-like device for cardiovascular treatment. It uses a smart stapling mechanism that enables multiple staples to simultaneously penetrate the stent graft and the aortic wall. With a small profile delivery system, the device, Aortoseal is quickly deployed via a single release action. It enables the implementation of endograft procedures in almost all types of anatomies and can dramatically reduce complications and reinterventions.
- Jul 2024Series A$10M
- Feb 2023Grant (prize money)$2.7M
- 2022Grant (prize money)$2.8M
- Dec 2021Seed$5M
#4
Acquired · Kfar Saba, Central District · founded 2013 · 74 employees$150.8Mraised▾
CathWorks is developing FFRAngio, a novel technology for angiogram-based physiology measurement that does not require pressure wires or hyperemic stimulus. It is based on the processing of visual information and automatic multi-layered algorithms. Its technology is focused on improving the utilization of coronary angiography data to validate measurement-based medicine in the cath lab.
- Jul 2022Series E$75M
- Jan 2021Series D$30M
- Feb 2019Series C$30M
- Oct 2017Series B$15.8M
#5
Series D · Rehovot, Central District · founded 2009 · 50 employees$40Mraised▾
Pi-cardia manufactures non-implant devices for valve repair. The product Leaflex provides lines that create separation between the calcium deposits on the two sides of the scoring line, in order to regain leaflets flexibility, allow their mobility and improve valve hemodynamics.
- Apr 2020Series D$27M
- Dec 2018Series C$3M
- Jan 2016Series C$10M
#6
Series C · Rehovot, Central District · founded 2012 · 20 employees$20Mraised▾
Laminate medical produces VasQ, a device designed to improve maturation and patency rates of AV fistulas. It provides external support thereby addressing the root causes of fistula failure. Failure is often due to clotting and thrombosis of the fistula which is caused by turbulent flow patterns around the anastomosis region, which VasQ prevents. Early failure occurs in over 40% of fistulas created using conventional techniques.The VasQ is not available in the US
- Oct 2019Series C—
- Jan 2019Series C$12M
- Feb 2017Series B$8M
- Mar 2016Grant (prize money)$56.6K
#7
Series B · Petah Tikva, Central District · founded 1996 · 24 employees$33.2Mraised▾
Provider of non-invasive sensing technology for body vitals measurement. The company develops and commercializes patient monitoring solutions for non-invasive continuous measurements of haemoglobin, oxygen saturation, glucose, and other blood parameters. Utilizing its proprietary Occlusion Spectroscopy technology, it also enables the monitoring of the oxygen saturation of Hb (SpO2), low signal oximetry, SpO2, pulse rate, plethysmogram, and haemoglobin. The system is designed for use in hospitals in operating and recovery rooms and intensive care units as well as in outpatient sites and emergency services.
#8
Series B · Netanya, Central District · founded 2005 · 12 employees$14.6Mraised▾
Angioslide has developed the Proteus device family that combines standard balloon angioplasty with debris removal capabilities through its suction mechanism. Distal embolization is a common complication of interventions to treat PAD. Angioslide helps physicians to manage embolic load released during procedures . The device enables physicians to capture and remove embolic particles dislodged at the lesion site in peripheral arteries through the device's Proteus Embolic capture feature which is integrated with the balloon. PROTEUS embolic capture feature involves a single-use suction mechanism that works through inward folding of the balloon, which creates negative pressure within the capture cavity for debris capture and removal. The reduced pressure in the capture cavity causes some of the particles that are released during the procedure to flow into the cavity for containment and removal. Used during angioplasty procedures. Product is both FDA and CE cleared for use in the lower limbs i.e. the femoral, iliac, ilio-femoral, popliteal, tibial, peroneal and profunda arteries.
- Jan 2013Series B$6.3M
- Oct 2009Series B$8.2M
#9
Acqui-Hired · Kfar Saba, Central District · founded 2008 · 11 employees$10Mraised▾
Kyma Medical Technologies develops patient monitoring solutions to improve care of patients suffering from chronic cardiac illnesses. The company has developed a proprietary technology for the detection and monitoring of changes in fluid contents, based on a proprietary RF sensing technology. Kyma’s solutions aim at providing healthcare professionals with accurate information on the patient's clinical status for support of medical decision-making. Kyma’s technology is currently applied via external use, and a subcutaneous approach is under development, thus meeting the needs of a variety of patient populations. The Kyma µ-Cor is CE Mark-approved for monitoring of one or more of the following clinical parameters: Thoracic Fluid Content, ECG, heart rate, respiratory rate, activity and body posture. As of November 2016, the device is not FDA approved and still under investigation in the US.
- Oct 2013Series A$10M
#10
Deadpooled · Rehovot, Central District · founded 2005$4.4Mraised▾
Ovalum focuses on the development and implementation of effective and safe solutions for chronic and acute total occlusions in the coronary and peripheral arteries. Based on proprietary shape memory alloy techniques and unique knowledge of laser processes, Ovalum claims that its systems will revolutionize the fields of minimally-invasive cardiology and interventional radiology.
- Sep 2006Series A$3.4M
- Dec 2005Seed$1M
#11
Series A · Petah Tikva, Central District · founded 2013 · 23 employees$3.5Mraised▾
Bendit Technologies, a JV between Lev Dies, Li-Med & Ozca Engineering Solutions is focussed on providing solutions to interventional radiologists and neuroradiologists for their minimally invasive procedures, such as endovascular coiling or chemoembolization. It has developed a steerable 2.7Fr peripheral/visceral microcatheter so as to achieve optimal navigation results in small outer diameters. It claims that catheter helps to shape the tube in any direction with controlled steering abilities ±1° spheric degree.
- Oct 2017Series A$3.5M
#12
Seed · Petah Tikva, Central District · founded 2008 · 7 employees$2.6Mraised▾
Leviticus Cardio has developed wireless power transfer system capable of providing the day-to-day power needs of available Ventricular Assist Device(VAD) implants. VAD, an implanted mechanical circulatory pump, is connected to an external power pack by a drive line. Infection related to the drive line represents the single most important challenge to extended VAD use. Leviticus Cardio has developed a Wireless Coplanar Energy Transfer (CET) system that provides the power needs of available VAD implants while avoiding the complications from infection associated with technologies.
- Jan 2019Grant (prize money)—
- Apr 2015Seed$1.5M
- Oct 2013Seed$1.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising